Cargando…
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study
OBJECTIVE: The effectiveness and safety of sirolimus for SLE treatment have been shown in some uncontrolled studies. However, a comparison of sirolimus with other classic immunosuppressants has not been reported. We conducted the study to compare the effectiveness and safety of sirolimus versus tacr...
Autores principales: | Jiang, Nan, Li, Mengtao, Zhang, Hongfeng, Duan, Xinwang, Li, Xiaofeng, Fang, Yongfei, Li, Hongbin, Yang, Pingting, Luo, Hui, Wang, Yanhong, Peng, Liying, Zhao, Jiuliang, Wu, Chanyuan, Wang, Qian, Tian, Xinping, Zhao, Yan, Zeng, Xiaofeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724817/ https://www.ncbi.nlm.nih.gov/pubmed/34980680 http://dx.doi.org/10.1136/lupus-2021-000617 |
Ejemplares similares
-
Annual Direct Cost and Cost-Drivers of Systemic Lupus Erythematosus: A Multi-Center Cross-Sectional Study from CSTAR Registry
por: Wang, Haiyan, et al.
Publicado: (2023) -
Chinese SLE Treatment and Research Group (CSTAR) Registry 2009–2019: Major Clinical Characteristics of Chinese Patients with Systemic Lupus Erythematosus
por: Li, Mengtao, et al.
Publicado: (2021) -
Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis
por: Peng, Liying, et al.
Publicado: (2020) -
Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus
por: Xiang, Yirong, et al.
Publicado: (2021) -
Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII
por: Gui, Yinli, et al.
Publicado: (2022)